Effects of the Combined Voglibose and Sulfonylurea Therapy on Insulin Secretion and Insulin Sensitivity in Non-Insulin-Dependent Diabetes Mellitus Patients.

概要

論文の詳細を見る
We investigated the effects of combination therapy with voglibose, a carbohydrase inhibitor, and a sulfonylurea (SU) drug in an open prospective study in 27 NIDDM patients. Fifteen patients were treated with voglibose combined with SU (combination group), while 12 patients were treated with SU alone (SU group). Insulin secretion and insulin sensitivity were measured before treatment and at week 4 of treatment. At the end of the study, plasma glucose concentrations had significantly decreased in both groups. Postprandial 2-hr glucose levels tended to be lower in the combination group than in the SU group. Insulin secretion measured by postprandial 2-hr C-peptide increased significantly from 3.7 ± 0.5 to 6.1 ±0.6 ng/m<I>l</I> in the SU group. In contrast, no change in postprandial C-peptide was observed (from 5.0±0.6 to 5.3±0.6 ng/m<I>l</I>) in the combination group. Insulin sensitivity (K index of the insulin tolerance test) significantly improved after combination therapy as well as in the SU group. Insulin sensitivity after combination therapy was comparable to that DI the SU group and lipid profiles after treatment improved only in the combination group. These results suggest that combination therapy using voglibose and a SU drug may reduce the risk of hyperinsulinism usually noted in patients treated only with a SU drug.
一般社団法人日本糖尿病学会の論文